Literature DB >> 2805552

Carbamazepine clearance in paediatric epilepsy patients. Influence of body mass, dose, sex and co-medication.

B Summers1, R S Summers.   

Abstract

Carbamazepine clearance was studied in Black paediatric epilepsy patients, 90 receiving monotherapy and 17 on combination therapy. For patients on monotherapy the following relationship are shown: clearance decreases with increasing body mass (r= 0.87); clearance increases with increasing dose (r = 0.70); and mean clearance for male are higher than those for females throughout the mass ranges, though the difference is not statistically significant. In the case of patients on carbamazepine plus another anticonvulsant, clearance also decreases with increasing body mass, and increases with increasing dose. Furthermore, in the mass groups which corresponded with those on monotherapy, mean carbamazepine clearance higher by a factor varying from 1.3 to 1.7; in the corresponding dosage groups, it is higher by a factor of between 1.4 and 1.7.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2805552     DOI: 10.2165/00003088-198917030-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  28 in total

1.  Carbamazepine: absorption, distribution, and excretion.

Authors:  P L Morselli
Journal:  Adv Neurol       Date:  1975

2.  Carbamazepine plasma levels in children and adults: influence of age, dose, and associated therapy.

Authors:  D Battino; L Bossi; D Croci; S Franceschetti; C Gomeni; A Moise; A Vitali
Journal:  Ther Drug Monit       Date:  1980       Impact factor: 3.681

3.  Single drug or combination therapy for epilepsy?

Authors:  E H Reynolds; S D Shorvon
Journal:  Drugs       Date:  1981-05       Impact factor: 9.546

4.  Effect of dose increments on serum carbamazepine concentration in epileptic patients.

Authors:  E Perucca; P Bittencourt; A Richens
Journal:  Clin Pharmacokinet       Date:  1980 Nov-Dec       Impact factor: 6.447

5.  Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses.

Authors:  M Eichelbaum; K Ekbom; L Bertilsson; V A Ringberger; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

6.  Carbamazepine metabolism in man. Induction and pharmacogenetic aspects.

Authors:  M Eichelbaum; T Tomson; G Tybring; L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

7.  Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication.

Authors:  B Rambeck; T May; U Juergens
Journal:  Ther Drug Monit       Date:  1987-09       Impact factor: 3.681

8.  Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique.

Authors:  L Bertilsson; B Höjer; G Tybring; J Osterloh; A Rane
Journal:  Clin Pharmacol Ther       Date:  1980-01       Impact factor: 6.875

9.  Population pharmacokinetics of phenytoin in South African black patients.

Authors:  R Miller; M Rheeders; C Klein; I Suchet
Journal:  S Afr Med J       Date:  1987-08-01

Review 10.  Carbamazepine efficacy and utilization in children.

Authors:  W E Dodson
Journal:  Epilepsia       Date:  1987       Impact factor: 5.864

View more
  9 in total

1.  Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses.

Authors:  Jae Eun Ahn; Angela K Birnbaum; Richard C Brundage
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

Review 2.  Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children.

Authors:  Natasa Djordjevic; Slobodan M Jankovic; Jasmina R Milovanovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

3.  Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.

Authors:  Trevor N Johnson; Amin Rostami-Hodjegan; Geoffrey T Tucker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis.

Authors:  T N Johnson; M S Tanner; C J Taylor; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2001-05       Impact factor: 4.335

5.  Population pharmacokinetics of carbamazepine in Singapore epileptic patients.

Authors:  E Chan; H S Lee; S S Hue
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

Review 6.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

8.  CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy.

Authors:  Natasa Djordjevic; Dragana Dragas Milovanovic; Marija Radovanovic; Ivan Radosavljevic; Slobodan Obradovic; Mihajlo Jakovljevic; Dragan Milovanovic; Jasmina R Milovanovic; Slobodan Jankovic
Journal:  Eur J Clin Pharmacol       Date:  2016-01-14       Impact factor: 2.953

9.  The influence of CYP2C8*3 on carbamazepine serum concentration in epileptic pediatric patients.

Authors:  D D Milovanovic; J R Milovanovic; M Radovanovic; I Radosavljevic; S Obradovic; S Jankovic; D Milovanovic; N Djordjevic
Journal:  Balkan J Med Genet       Date:  2016-08-02       Impact factor: 0.519

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.